• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.78% Nasdaq Down1.13%

    Cytori Therapeutics, Inc. (CYTX)

    0.27 Down 0.03(9.80%) May 3, 3:59PM EDT
    ProfileGet Profile for:
    Cytori Therapeutics, Inc.
    3020 Callan Road
    San Diego, CA 92121
    United States - Map
    Phone: 858-458-0900
    Website: http://www.cytori.com

    Index Membership:N/A
    Full Time Employees:78

    Business Summary 

    Cytori Therapeutics, Inc., a biotechnology company, develops cellular therapeutics for specific diseases and medical conditions. The company primarily provides Cytori Cell Therapy consisting of a heterogeneous population of specialized cells, including stem cells for the treatment of patients with scleroderma hand dysfunction, orthopedic disorders, urinary incontinence, and thermal burns combined with radiation injury. It also offers Celution System devices, proprietary enzymes, and sterile consumable sets to commercial customers, as well as for research customers developing new therapeutic applications for Cytori Cell Therapy in Europe, Japan, and other regions. In addition, the company provides StemSource devices, including a cryogenic freezer, measuring and monitoring equipment, and a database patient tracking system, as well as offers consulting, installation, and training services. Cytori Therapeutics, Inc. markets its products to hospitals, clinics, tissue banks, and stem cell banking companies through direct sales reps, distributors, and partners worldwide. The company was founded in 1996 and is headquartered in San Diego, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Cytori Therapeutics, Inc.

    Corporate Governance 
    Cytori Therapeutics, Inc.’s ISS Governance QuickScore as of Jul 1, 2015 is 5. The pillar scores are Audit: 10; Board: 7; Shareholder Rights: 2; Compensation: 7.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Dr. Marc H. Hedrick M.D., 53
    Chief Exec. Officer, Pres, Director and Member of Exec. Committee
    Mr. Tiago M. Girao , 37
    Chief Financial Officer and VP of Fin.
    Dr. Steven Kesten M.D., 58
    Chief Medical Officer and Exec. VP
    Dr. John K. Fraser Ph.D., 55
    Chief Scientist
    Mr. Jeremy Hayden ,
    VP of Bus. Devel. and Gen. Counsel
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders